Question:

A novel targeted therapy for prostate cancer is approved for use but faces challenges in terms of cost and availability. What is the most effective strategy to address these barriers and ensure equitable access to the treatment?

Answer: How did you do?? Click here to find out or post your answer below!

1 - Increase the price of the drug to ensure profitability.

2 - Limit the use of the drug to patients with specific genetic profiles.

3 - Develop patient assistance programs to support treatment costs.

4 - Prioritize access to the drug for patients in academic centers.

5 - Discontinue the use of the drug due to accessibility challenges.

Can you answer the questions about this case? Watch Prof Gain's session, who chairs a discussion on this topic in our Advanced Prostate Cancer Course

Mr. Taylor is a 79-year-old retired chef with a history of chronic kidney disease, congestive heart failure, and COPD. He recently presented to his primary care physician with new-onset back pain and urinary difficulties. Examination revealed mid-back tenderness and a diffusely enlarged prostate. His PSA level was markedly elevated at 65.4 ng/mL.

This program is funded by an independent grant from Merck. This online education program has been designed solely for healthcare professionals in USA. The content is not available for healthcare professionals in any other region.

Can you answer the questions about this case? Watch Prof Gain's session, who chairs a discussion on this topic in our Advanced Prostate Cancer Course

Mr. Smith, a 65-year-old retired teacher in good overall health, presented for his annual checkup. His routine blood work revealed an increasing trend in his prostate-specific antigen (PSA) levels over the past two years. After experiencing increased urinary frequency and nocturia, he was referred to a urologist. An MRI revealed a lesion in the left posterior peripheral zone of the prostate with suspected extraprostatic extension. A subsequent MRI fusion biopsy confirmed high-risk prostate cancer (Grade Group 4). A PSMA-PET scan further revealed an avid lymph node and sclerotic bone metastasis, indicating early (oligo) metastatic disease.

This program is funded by an independent grant from Merck. This online education program has been designed solely for healthcare professionals in USA. The content is not available for healthcare professionals in any other region.

MedAll Oncology has been created to encourage community for all those on MedAll with an interest in Oncology. Please feel free to create your own thread to chat with others.Maybe you have come across some interesting documentation you want to share, maybe you are doing some research and looking for colleagues.

Lets see what we can do with threads!

By following MedAll Oncology you will be kept up to date on all the comings and goings within this group!

We love to chat and hope you do too!

Enhance your understanding of sarcoma by attending the insightful webinar titled, "Sarcoma Insights: Diagnosis to Management”, led by Dr. Georgina Wood. This session focuses on sarcoma's epidemiology, diagnosis and the latest treatment principles. Suitable for healthcare professionals, this learning activity is an opportunity to enrich your knowledge about sarcoma and improve patient outcomes in this specialized field. It's also important to note that the faculty and planners for this event do not have any financial ties to ineligible healthcare product companies.

We are always looking for ideas about how we can help our community to develop in their professional careers while advancing the quality of patient care we can provide collectively. Please take a moment to let us know what topics you think we should cover.

Welcome to MedAll Oncology. Why not take some time to introduce yourself, let us know what you do, where you come from and what your healthcare interests are.